Table I.
Characteristics of study participants*
| Asthma |
|||
|---|---|---|---|
| Characteristic | EIB+ (n = 10) | EIB− (n = 10) | P value |
| Age (y) | |||
| Mean | 26.6 | 32.5 | .21 |
| Range | 20-28 | 20-54 | |
| Sex (% male) | 60 | 30 | .18 |
| Race | |||
| White | 9 | 8 | |
| African American | 0 | 1 | |
| Asian | 1 | 0 | |
| Hispanic | 0 | 1 | |
| Clinical features | |||
| Asthma Exacerbations/y | 0 | 0 | NS |
| Prior ICS use (%) | 50 | 40 | .50 |
| Allergic rhinitis (%) | 40 | 20 | .31 |
| Baseline | |||
| FEV1 (%) | 81.7 ± 10.3 | 80.9 ± 11.3 | .87 |
| FVC (%) | 99.1 ± 10.9 | 97.8 ± 10.1 | .79 |
| FEV1/FVC | 0.7 ± 0.1 | 0.7 ± 0.1 | .96 |
| FEF25-75 (%) | 54.0 ± 16.5 | 55.0 ± 14.7 | .89 |
| After bronchodilator | |||
| Δ FEV1 (%) | 13.3 ± 7.1 | 14.3 ± 11.3 | .81 |
| Δ FVC (%) | 3.7 ± 9.0 | 2.4 ± 7.7 | .72 |
| Δ FEV1/FVC (%) | 11.0 ± 6.8 | 11.8 ± 7.7 | .79 |
| Δ FEF25-75 (%) | 38.8 ± 20.4 | 32.9 ± 20.9 | .53 |
| After exercise | |||
| Maximum decrease in FEV1 | −37.2 ± 5.3 | −3.1 ± 3.1 | <.001 |
| Area under FEV1 curve† | −879.3 ± 220.6 | 48.5 ± 96.1 | <.001 |
FVC, Forced vital capacity; FEF25-75, forced expiratory flow, midexpiratory phase.
*
Values are reported as means ± SD unless otherwise specified.
†
Area under the FEV1 curve over the first 30 minutes after exercise (percentage change × min).